Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

Virealize340 Aug. 26 at 7:05 PM

$IMNN this one got me between the wall all I know we need to hold that $6 as strong as we could

0 · Reply

I_AM_GROOT Aug. 26 at 5:24 PM

$IMNN I mean they could have grabbed 50 mil when it was trading at 9. Would have been the end of the money talk for a yr or so. But no.. and there lies the friggin problem with the BOD and Managment. Just mind blowing how abusive they are with stock managment. Alarming abusive

0 · Reply

donoho1 Aug. 26 at 5:23 PM

$IMNN Why don’t they offer options on this POS. I need to get my money back.

0 · Reply

bomber1 Aug. 26 at 5:13 PM

$IMNN Do you know why it goes down every day? According to you idiot bulls, can it ever make an offering at $8 or $10 or even $15, or is it more logical, idiots, that it will make an offering at $1? ... Are you bulls thinking beings, or are you just drugged and imbued with the lies that Stacy Lindgorg tells? ... Think about it and you will see that it is as I say; they need money; more money; always money; and how do they get it? With church offerings? Or with a capital increase?

1 · Reply

Goldpay55 Aug. 26 at 4:23 PM

$IMNN come on $5

0 · Reply

3ARated Aug. 26 at 4:14 PM

$IMNN Slow bleed

0 · Reply

Goldpay55 Aug. 26 at 3:30 PM

$IMNN does anyone know if they have dosed more than 1 patient yet? Sure would like to know if they are moving according to plan

0 · Reply

bomber1 Aug. 26 at 3:12 PM

$IMNN Come on, tomorrow it'll go up!! Yes, of course! Today it'll go down, tomorrow it'll go up; ... bullish people, your day is tomorrow, not today...

0 · Reply

Trinity031983 Aug. 26 at 1:41 PM

$IMNN Aiff is flying right now, let’s go and make it going to the moon

0 · Reply

Goldpay55 Aug. 25 at 6:46 PM

$IMNN headed for another RS I would think. Nothing good seems to

0 · Reply

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 21 days ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 21 days ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 27 days ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 4 weeks ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 4 weeks ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 4 weeks ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 6 weeks ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 2 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 3 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 3 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 3 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 3 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 3 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 3 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 4 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 5 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 6 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 6 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 6 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 6 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 6 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 7 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 8 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 9 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 9 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 5:11 PM EST - 10 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:00 AM EST - 10 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 8:05 AM EST - 10 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024, 8:30 AM EDT - 10 months ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 30, 2024, 9:05 AM EDT - 10 months ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 7, 2024, 8:05 AM EDT - 11 months ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2024, 4:06 PM EDT - 1 year ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Aug 28, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Host R&D Day on September 18th

Aug 14, 2024, 2:55 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 5:04 PM EDT - 1 year ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Jul 30, 2024, 1:07 PM EDT - 1 year ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 9:42 AM EDT - 1 year ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 8:00 AM EDT - 1 year ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Jul 29, 2024, 4:05 PM EDT - 1 year ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Jun 24, 2024, 8:30 AM EDT - 1 year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Jun 5, 2024, 8:30 AM EDT - 1 year ago

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Virealize340 Aug. 26 at 7:05 PM

$IMNN this one got me between the wall all I know we need to hold that $6 as strong as we could

0 · Reply

I_AM_GROOT Aug. 26 at 5:24 PM

0 · Reply

donoho1 Aug. 26 at 5:23 PM

$IMNN Why don’t they offer options on this POS. I need to get my money back.

0 · Reply

bomber1 Aug. 26 at 5:13 PM

1 · Reply

Goldpay55 Aug. 26 at 4:23 PM

$IMNN come on $5

0 · Reply

3ARated Aug. 26 at 4:14 PM

$IMNN Slow bleed

0 · Reply

Goldpay55 Aug. 26 at 3:30 PM

$IMNN does anyone know if they have dosed more than 1 patient yet? Sure would like to know if they are moving according to plan

0 · Reply

bomber1 Aug. 26 at 3:12 PM

$IMNN Come on, tomorrow it'll go up!! Yes, of course! Today it'll go down, tomorrow it'll go up; ... bullish people, your day is tomorrow, not today...

0 · Reply

Trinity031983 Aug. 26 at 1:41 PM

$IMNN Aiff is flying right now, let’s go and make it going to the moon

0 · Reply

Goldpay55 Aug. 25 at 6:46 PM

$IMNN headed for another RS I would think. Nothing good seems to

0 · Reply

Goldpay55 Aug. 25 at 6:45 PM

$IMNN lol thats a funny one

0 · Reply

Shrekislove69 Aug. 25 at 3:17 PM

$IMNN when 60$

1 · Reply

ConcernedCitizen23 Aug. 25 at 2:35 PM

$IMNN don’t forget imunon has a covid dna vaccine that could become pretty hot once the mRNA vaccines get cancelled by Trump

1 · Reply

gepetto123 Aug. 25 at 12:03 PM

$IMNN why i can't sell this?

1 · Reply

ConcernedCitizen23 Aug. 24 at 12:08 PM

$IMNN phase 3 might take some time but people forgot that they have another phase 2 expected to finish next year in premier places like Sloan Kettering, md Anderson and Johns Hopkins too. Check for yourself.

1 · Reply

Mad_Macks Aug. 23 at 12:00 AM

$IMNN not many divi winners sold. LFG 💪🏻Oct/Nov is gonna rock. Ppl with cancer will survive longer. Hope is alive. Remember that’s what this is about. W

1 · Reply

Goldpay55 Aug. 22 at 4:56 PM

$IMNN maybe they will report whe the 2nd patient is dosed.

0 · Reply

donoho1 Aug. 22 at 4:36 PM

$IMNN Wow. I’m up 25.88 today because of dividend. Done big time because of R/S and dilution. Go up dammit.

0 · Reply

Goldpay55 Aug. 22 at 3:32 PM

$IMNN so it looks like the excitement is over for another

0 · Reply

nlstbro Aug. 22 at 3:09 PM

$IMNN

0 · Reply

esinglady Aug. 22 at 1:16 PM

$IMNN is this going to move today? Seems stuck lol

0 · Reply

Shrekislove69 Aug. 22 at 1:15 PM

$IMNN holding for a while now. Gonna forget about it till late fall!!

0 · Reply

Market Cap	15.87M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,500
Avg Vol	254,741
Day's Range	N/A - N/A
Shares Out	2.44M
Stochastic %K	19%
Beta	2.16
Analysts	Strong Sell
Price Target	$31.63